Compare Sanofi SA (SNY) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs UnitedHealth Group Inc — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while UnitedHealth Group Inc trades at $393.96 (market cap $359.79B). The key difference: UnitedHealth Group Inc is far larger — about 3.5× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | UNH | |
|---|---|---|
Market Cap | $104.06B | $359.79B |
Sector | Health | Health |
52-Week High | $52.34 | $436.35 |
52-Week Low | $41.33 | $259.02 |
Enterprise Value | $124.09B | $401.65B |
Dividend Yield | 5.61% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
UnitedHealth Group (UNH) trades at $393.06, down 1.03% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $447.57B in 2025, with net income of $12.06B, and has beaten EPS estimates in recent quarters. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
The outlook for UNH is positive, driven by aging demographics, Medicare growth, and operational efficiencies, though risks include regulatory scrutiny and margin pressures. With 82.7% of analysts rating it a buy and a consensus price target of $475.47, the stock presents a compelling opportunity for long-term investors seeking exposure to healthcare stability and dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
